普伐他汀联合罗格列酮治疗早期糖尿病肾病的疗效观察  

Curative effectiveness of pravastatin combined with rosiglitazone for patients with early stage of diabetic kidney disease

作　　者：卢丽[1] 刘晶晶[1] 袁海[1] 

机构地区：[1]湖北省襄阳市中心医院肾内科,441021

出　　处：《临床肾脏病杂志》2012年第5期223-225,共3页Journal Of Clinical Nephrology

摘　　要：目的观察普伐他汀联合罗格列酮治疗早期糖尿病肾病的临床疗效。方法糖尿病肾病患者88例，随机均分为普伐他汀治疗组、联合治疗组。其中普伐他汀治疗组给予普伐他汀40mg／d，联合组在普伐他汀治疗基础上加用罗格列酮4mg／d，治疗时间6个月。所有研究对象分别于治疗前及治疗后各采静脉血1次，测定血清胰岛素抵抗指数和三酰甘油、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇，治疗前、后测尿白蛋白排泄率。结果两组高密度脂蛋白胆固醇治疗后均升高（P〈0．05），其余各项指标在治疗后均明显低于治疗前（P〈0．05），联合治疗组各项指标较普伐他汀治疗组变化更为显著（P〈0．05）。结论普伐他汀能抑制早期糖尿病肾病的发展，联合罗格列酮作用更为显著。Objective To observe the clinical effectiveness of pravastatin combined with rosiglitazone for patients with early stage of diabetic nephropathy（DN）. Methods Eighty-eight cases of DN were randomly divided into pravastatin（40 mg/day）group,and pravastatin（40 mg/day） ＋ rosiglitazone （4 rag/day） group. The treatment duration was 6 months. Serum insulin resistant index, total cholesterol,low-density lipoprotein cholesterol and high-density lipoprotein cholesterol, and urinary albumin excretion rate were measured before and after treatment. Results Serum high-density lipoprotein cholesterol levels in both two groups were significantly increased after treatment（P〈0. 05）, and the rest indicators were significantly reduced after treatment as compared with those before treatment（P〈 0. 05）. The changes of the indicators in pravastatin ＋ rosiglitazone group were more significant than in pravastatin group（P〈0. 05）. Conclusions Pravastatin can inhibit the progression of early stage of DKD, and its combined use with rosiglitazone can exert more significant effect.

关 键 词：糖尿病肾病 治疗 胆固醇 

分 类 号：R587.2[医药卫生—内分泌]